A randomized,placebo-controlled,single ascending-dose study to assess the safety,tolerability, pharmacokinetics,and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers |
| |
Affiliation: | 1. MedImmune, Cambridge, UK;2. MedImmune, Gaithersburg, MD, USA;3. AstraZeneca, Cambridge, UK;4. AstraZeneca K.K., Osaka, Japan;5. MedImmune, Mountain View, CA, USA;6. California Clinical Trials Medical Group, Inc., Glendale, CA, USA |
| |
Abstract: | Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subcutaneous tralokinumab (150, 300, or 600 mg) in thirty healthy Japanese adults. The most frequent treatment-emergent adverse event (TEAE) in all treatment groups was injection-site pain. The frequency and severity of TEAEs was similar across tralokinumab doses. Cmax, AUC(0–t), and AUC(0–inf) increased in a dose-proportional manner, and mean t1/2 ranged from 20 to 25 days. No anti-drug antibodies were detected. A post-hoc pooled population PK modeling analysis, incorporating PK data from this study, demonstrated that Japanese individuals had greater systemic exposure to tralokinumab than non-Japanese individuals. This difference was not clinically relevant and was primarily due to differences in body weight, with lower body weight associated with greater PK exposure. Japanese ethnicity was not a significant predictor of tralokinumab PK. This study indicates that single-dose subcutaneous administration of tralokinumab 150–600 mg was well tolerated in Japanese healthy volunteers, and supports the 300 mg dose selection for Japanese patients with asthma in ongoing clinical trials. |
| |
Keywords: | Asthma Clinical trial IL-13 Japanese Pharmacokinetics Tolerability Tralokinumab |
本文献已被 ScienceDirect 等数据库收录! |
|